Cambridge, Mass.– Predicta Biosciences and CIMA LAB Diagnostics from the Clínica Universidad de Navarra have announced a partnership to offer a combined diagnostic service for multiple myeloma and other hematological malignancies.
The service will integrate CIMA LAB’s flow cytometry capabilities with Predicta’s GenoPredicta™ assay. It will be available to academic institutions and biopharma partners across Spain and the European Union.
CIMA LAB Diagnostics’ Flow Cytometry Unit, led by Dr. Bruno Paiva, has recognized expertise in the diagnosis and monitoring of hematologic malignancies. Flow cytometry is widely used for differential diagnosis, prognostic classification and monitoring minimal residual disease, or MRD, across multiple blood cancers.
“This partnership with CIMA LAB Diagnostics will accelerate and expand the availability of our GenoPredicta platform for EU partners,” said Brian McKernan, CEO of Predicta Biosciences. “Dr. Paiva has been an outstanding collaborator, and we are excited about what this relationship with CIMA LAB Diagnostics will bring to the future of blood cancer diagnostics.”
“We are honored and very excited to partner with Predicta Biosciences. The GenoPredicta assay is the optimal solution for a missing element in our quest for innovation and improved diagnosis and monitoring of patients with blood cancer. With this partnership, not only can we detect and quantify rare tumor clones, but also characterize their genome at the single-cell level. This is a novel and extremely powerful tool for precision medicine across different types of blood cancer,” said Dr. Bruno Paiva.
Paiva will present an update on the GenoPredicta platform at the European Hematology Association Congress, taking place June 11-14 in Stockholm and virtually. His presentation, PF787, is titled “Whole Genome Sequencing of Multiple Myeloma Cells with a Novel Clinical Assay Uncovers Diversity of Genetic Alterations Underlying Immunotherapy Resistance.”
